secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001725160-26-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis reports FY2025 results; cash $245.9M, DENALI Part 2 topline due year-end 2026
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $245.9M as of Dec 31, 2025; projected runway into late 2027.
- R&D expenses $107.3M (down 36% YoY); G&A expenses $37.7M (down 57% YoY).
- DENALI Part 2a enrollment completed; monotherapy dose confirmation expected 1H 2026.
- DENALI Part 2 topline readout on track for year-end 2026; potential to support accelerated approval.
- ASPENOVA Phase 3 confirmatory trial (azenosertib vs chemo in Cyclin E1+ PROC) to initiate 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000010/0001725160-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000010/zntl-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001725160-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer